Skip to content
10-Q

Quarterly Report

Corvus Pharmaceuticals, Inc. CRVS

0001104659-26-057100

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 84.09M sh
Shares Diluted Q1 2026 · Mar 31, 2026 90M sh
Shares Diluted Q1 2026 · Mar 31, 2025 75.15M sh
Capex Q1 2026 · Mar 31, 2026 $91K
Capex Q1 2026 · Mar 31, 2025 $36K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$10.37M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.26M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $40.1M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.58M
Stockholders Equity Q1 2026 · Mar 31, 2026 $240.68M
Stockholders Equity Q1 2026 · Dec 31, 2025 $61.21M
Stockholders Equity Q1 2026 · Mar 31, 2025 $49.33M
Stockholders Equity Q1 2026 · Dec 31, 2024 $32.57M
Current Liabilities Q1 2026 · Mar 31, 2026 $12.11M
Current Liabilities Q1 2026 · Dec 31, 2025 $9.38M
Total Liabilities Q1 2026 · Mar 31, 2026 $12.52M
Total Liabilities Q1 2026 · Dec 31, 2025 $9.91M
Current Assets Q1 2026 · Mar 31, 2026 $239.95M
Current Assets Q1 2026 · Dec 31, 2025 $58.21M
Total Assets Q1 2026 · Mar 31, 2026 $253.2M
Total Assets Q1 2026 · Dec 31, 2025 $71.12M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.15
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.13
Eps Basic Q1 2026 · Mar 31, 2026 −$0.15
Eps Basic Q1 2026 · Mar 31, 2025 $0.21
Sga Expense Q1 2026 · Mar 31, 2026 $3.7M
Sga Expense Q1 2026 · Mar 31, 2025 $2.47M
Rd Expense Q1 2026 · Mar 31, 2026 $11.18M
Rd Expense Q1 2026 · Mar 31, 2025 $7.45M
Net Income Q1 2026 · Mar 31, 2026 −$13.69M
Net Income Q1 2026 · Mar 31, 2025 $15.19M
Operating Income Q1 2026 · Mar 31, 2026 −$14.88M
Operating Income Q1 2026 · Mar 31, 2025 −$9.92M